In vitro, CM-101 was shown to attenuate migration and activation of dermal fibroblasts and to inhibit the activation of endothelial cells.57 Additional studies also showed that silencing CCL24 using shRNA affected tube formation, which further supports CCL24-related effects on vasculopathy.54,57 Taken together, the preclinical data highlight the important role of CCL24 in inflammation, fibrosis, and vasculopathy, suggesting that CCL24 could be a potential therapeutic target in SSc as well as in other fibrotic inflammatory diseases (Figure 1). Here, CCL24 is linked to systemic sclerosis.